{"name":"MEDRx USA, Inc.","slug":"medrx-usa-inc","ticker":"","exchange":"","domain":"","description":"MEDRx USA, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative pain management solutions. The company has a pipeline of three phase 3 drugs, including etodolac-lidocaine topical patches, aimed at addressing significant unmet needs in the market.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Etodolac-lidocaine topical patch","genericName":"Etodolac-lidocaine topical patch","slug":"etodolac-lidocaine-topical-patch","indication":"Localized musculoskeletal pain and inflammation","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"MRX-7EAT","genericName":"MRX-7EAT","slug":"mrx-7eat","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"Etodolac-lidocaine topical patch","genericName":"Etodolac-lidocaine topical patch","slug":"etodolac-lidocaine-topical-patch","phase":"phase_3","mechanism":"Etodolac-lidocaine topical patch delivers a nonsteroidal anti-inflammatory drug (NSAID) and local anesthetic directly to affected tissue to reduce pain and inflammation.","indications":["Localized musculoskeletal pain and inflammation","Osteoarthritis pain (localized)"],"catalyst":""},{"name":"MRX-7EAT","genericName":"MRX-7EAT","slug":"mrx-7eat","phase":"phase_3","mechanism":"MRX-7EAT is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE1aOWRXYWZEMUhZeTQ2VWVFcU9Hc1QtZk1ReC1SckRNMG9ENHVGeldfeV9leHY2Z0tqUFIzeFA0UW9hLTlZNDdlVFlzV1VhY3dyY2Eza1NVVC1ObEFlTWU0UEx6c1JFN3VRd1NHOGRfUHdhaDg?oc=5","date":"2020-08-18","type":"pipeline","source":"marketscreener.com","summary":"MedRx Co., Ltd Stock (4586) - Quote Japan Exchange - marketscreener.com","headline":"MedRx Co., Ltd Stock (4586) - Quote Japan Exchange","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}